RUNX2 and Hepatic fibrosis: The use of a selective p38 mitogen-activated protein kinase (MAPK)inhibitor has been shown to ameliorate liver fibrosis through the downregulationof RUNX2 in rat models [67], indicating its pivotal role in fibrogenic processes[68, 69].